Osimertinib Shows Cost-Effectiveness in China but Not US for Stage III EGFR-Mutant NSCLC After Chemoradiotherapy

A new international cost-effectiveness analysis has revealed significant disparities in the economic viability of osimertinib查看药品详情 consolidation therapy for patients with stage III EGFR (搜索)搜索该靶点-mutated non-small cell lung cancer (NSCLC) following chemoradiotherapy, with the treatment proving cost-effective in China but not in the United States.

The study, published in Frontiers in Public Health, analyzed data from the landmark LAURA Phase 3 clinical trial, which demonstrated that osimertinib查看药品详情 significantly improved progression-free survival (PFS) compared to placebo (搜索)搜索该药品 in patients with sensitizing EGFR (搜索)搜索该靶点 mutations and stage III unresectable NSCLC without progressive disease after chemoradiotherapy.

LAURA Trial Results Drive Economic Analysis

The LAURA trial showed osimertinib查看药品详情 achieved a median PFS of 38.9 months versus 7.3 months with placebo (搜索)搜索该药品, representing a hazard ratio of 0.19 (95% CI, 0.12 to 0.29) and an 81% reduction in disease progression and death. While overall survival data have not yet reached maturity, interim analyses showed a trend toward OS benefit in the osimertinib group with a 19% decrease in the risk of death (HR, 0.81; 95% CI, 0.42 to 1.56).

The majority of patients in both treatment groups received subsequent osimertinib查看药品详情 treatment after disease progression, with 42 cases (29.4%) in the osimertinib group and 57 cases (78.1%) in the placebo (搜索)搜索该药品 group receiving subsequent systemic anticancer therapy.

Stark Cost-Effectiveness Differences Between Countries

Using a 15-year Markov model with willingness-to-pay thresholds of $150,000/QALY for the US and $39,632/QALY for China, researchers found dramatically different economic outcomes between the two healthcare systems.

In China, osimertinib查看药品详情 demonstrated cost-effectiveness with an incremental cost-effectiveness ratio (ICER) of $35,186/QALY and an incremental net health benefit (INHB) of 0.06 QALYs. The total treatment cost for the osimertinib group was $49,565, with patients gaining an additional 0.39 life years (4.68 months) and 0.51 quality-adjusted life years compared to placebo (搜索)搜索该药品.

Conversely, in the United States, osimertinib查看药品详情 was not cost-effective, with an ICER of $322,308/QALY and a negative INHB of -0.63 QALYs. The total treatment cost reached $898,107, though patients still gained 0.45 life years (5.40 months) and 0.56 QALYs compared to placebo (搜索)搜索该药品.

Sensitivity Analysis Reveals Key Factors

One-way sensitivity analyses identified health utility values as the primary factor affecting ICER values in both countries, surpassing even the cost of osimertinib查看药品详情 itself. In the US, when the PFS utility value ranged from 0.6328 to 0.9492, the ICER per QALY varied between $208,346 and $711,474, consistently exceeding the willingness-to-pay threshold.

Probabilistic sensitivity analysis indicated that osimertinib查看药品详情 had a 21.1% likelihood of being cost-effective in the US and 50.0% in China at their respective willingness-to-pay thresholds. The cost-effectiveness acceptability curves showed that when WTP thresholds increased to approximately $400,000 in the US and $45,000 in China, the probability of cost-effectiveness approached 60% in both settings.

Subgroup Analysis Reveals Patient-Specific Outcomes

Subgroup analyses in the United States showed that most patient groups had ICER values exceeding WTP thresholds, with two notable exceptions. Patients aged 65 years and older showed an ICER of $134,526 with an INHB of 0.05 QALYs, while those with L858R (搜索)搜索该靶点 EGFR (搜索)搜索该靶点 mutations had an ICER of $146,821/QALY with an INHB of 0.01 QALYs.

In China, ICER values remained below WTP thresholds across all analyzed patient subgroups, with osimertinib查看药品详情 demonstrating superior cost-effectiveness as the optimal treatment for patients with unresectable stage III EGFR (搜索)搜索该靶点-mutated NSCLC without disease progression after chemoradiotherapy.

Healthcare System Differences Drive Economic Disparities

The study highlighted fundamental differences between the US and Chinese healthcare systems that contribute to these economic disparities. China's per-capita health expenditure was $672.5 compared to $12,434.4 in the United States in 2022. The US healthcare system operates primarily through private insurance with market-driven drug pricing, while China's government-led system sets drug prices through state regulation and national policy.

The researchers noted that in China, due to uneven economic development across regions, WTP thresholds vary significantly. At the national threshold of $39,632/QALY, osimertinib查看药品详情 remains cost-effective in most eastern and central provinces, while placebo (搜索)搜索该药品 may be more suitable in less developed northeastern and western regions.

Clinical Context and Future Implications

Approximately one-third of patients with unresectable stage III NSCLC (搜索)搜索该疾病 treated with chemoradiotherapy have EGFR (搜索)搜索该靶点 mutations worldwide, with rates varying from 30-50% in East Asian countries to 8-21% in the United States. These patients typically experience higher rates of distant metastasis despite better response rates to chemoradiotherapy compared to those with wild-type EGFR.

The study's findings suggest that regulatory approval and inclusion in national reimbursement drug lists will be essential steps to enhance access to osimertinib查看药品详情 in China, while in the United States, pharmaceutical companies may need to re-evaluate pricing strategies to improve cost-effectiveness and market competitiveness.

The analysis provides crucial guidance for healthcare policymakers and clinicians in different economic settings, emphasizing the importance of region-specific cost-effectiveness evaluations for precision medicine approaches in lung cancer treatment.